229 related articles for article (PubMed ID: 18330084)
1. Mangafodipir-DPDP enhanced MRI visualization of a pancreatic adenocarcinoma previously undetected by extracellular contrast enhanced CT and MRI.
De Filippo M; Bocchi C; Quartieri L; Corradi D; Zompatori M
Acta Biomed; 2007 Dec; 78(3):225-8. PubMed ID: 18330084
[TBL] [Abstract][Full Text] [Related]
2. Secretin-stimulated multi-detector CT versus mangafodipir trisodium-enhanced MR imaging plus MRCP in characterization of non-metastatic solid pancreatic lesions.
Boraschi P; Donati F; Gigoni R; Salemi S; Faggioni L; Del Chiaro M; Boggi U; Bartolozzi C; Falaschi F
Dig Liver Dis; 2009 Nov; 41(11):829-37. PubMed ID: 19303825
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT.
Schima W; Függer R; Schober E; Oettl C; Wamser P; Grabenwöger F; Ryan JM; Novacek G
AJR Am J Roentgenol; 2002 Sep; 179(3):717-24. PubMed ID: 12185052
[TBL] [Abstract][Full Text] [Related]
4. Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET.
Sahani DV; Kalva SP; Fischman AJ; Kadavigere R; Blake M; Hahn PF; Saini S
AJR Am J Roentgenol; 2005 Jul; 185(1):239-46. PubMed ID: 15972430
[TBL] [Abstract][Full Text] [Related]
5. MRI with mangafodipir trisodium in the detection of pancreatic tumours: comparison with helical CT.
Rieber A; Tomczak R; Nüssle K; Klaus H; Brambs HJ
Br J Radiol; 2000 Nov; 73(875):1165-9. PubMed ID: 11144793
[TBL] [Abstract][Full Text] [Related]
6. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas.
Wang C
Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956
[TBL] [Abstract][Full Text] [Related]
7. Identification and staging of pancreatic tumours using computed tomography, endoscopic ultrasound and mangafodipir trisodium-enhanced magnetic resonance imaging.
Ramsay D; Marshall M; Song S; Zimmerman M; Edmunds S; Yusoff I; Cullingford G; Fletcher D; Mendelson R
Australas Radiol; 2004 Jun; 48(2):154-61. PubMed ID: 15230749
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance with manganese-DPDP (mangafodipir) of focal solid pancreatic lesions.
Zanello A; Nicoletti R; Brambilla P; Boccuni R; Di Carlo V; Staudacher C; Del Maschio A
Radiol Med; 2004 Sep; 108(3):194-207. PubMed ID: 15343134
[TBL] [Abstract][Full Text] [Related]
9. MRI with mangafodipir trisodium in the detection and staging of pancreatic cancer.
Romijn MG; Stoker J; van Eijck CH; van Muiswinkel JM; Torres CG; Laméris JS
J Magn Reson Imaging; 2000 Aug; 12(2):261-8. PubMed ID: 10931589
[TBL] [Abstract][Full Text] [Related]
10. Functioning acinar cell pancreatic carcinoma: diagnosis on mangafodipir trisodium (Mn-DPDP)-enhanced MRI.
Sahani D; Prasad SR; Maher M; Warshaw AL; Hahn PF; Saini S
J Comput Assist Tomogr; 2002; 26(1):126-8. PubMed ID: 11801915
[TBL] [Abstract][Full Text] [Related]
11. Mangafodipir trisodium-enhanced magnetic resonance imaging for evaluation of pancreatic mass and mass-like lesions.
Eser G; Karabacakoglu A; Karakose S; Eser C; Kayacetin E
World J Gastroenterol; 2006 Mar; 12(10):1603-6. PubMed ID: 16570354
[TBL] [Abstract][Full Text] [Related]
12. [MR imaging of pancreatic lesions with Mn-DPDP. A histopathologic correlation].
Dobritz M; Fellner FA; Baum U; Nömayr A; Lell M; Klein P; Papadopoulos T; Bautz W
Rofo; 2002 Jul; 174(7):893-7. PubMed ID: 12101481
[TBL] [Abstract][Full Text] [Related]
13. Mn-DPDP in MR imaging of pancreatic adenocarcinoma: initial clinical experience.
Gehl HB; Urhahn R; Bohndorf K; Klever P; Hauptmann S; Lodemann KP; Matern S; Schumpelick V; Günther RW
Radiology; 1993 Mar; 186(3):795-8. PubMed ID: 8430190
[TBL] [Abstract][Full Text] [Related]
14. Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging.
Rofsky NM; Earls JP
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):73-85. PubMed ID: 8673718
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of focal pancreatic masses: comparison of mangafodipir-enhanced MR imaging and contrast-enhanced helical CT.
Schima W; Függer R
Eur Radiol; 2002 Dec; 12(12):2998-3008. PubMed ID: 12439582
[TBL] [Abstract][Full Text] [Related]
16. [Resectability of pancreatic head adenocarcinoma].
Lévy P
Gastroenterol Clin Biol; 2001 Sep; 25(2 Pt 2):C19-23. PubMed ID: 11787375
[No Abstract] [Full Text] [Related]
17. Pancreatic enhancement and pulse sequence analysis using low-dose mangafodipir trisodium.
Mayo-Smith WW; Schima W; Saini S; Slater GJ; McFarland EG
AJR Am J Roentgenol; 1998 Mar; 170(3):649-52. PubMed ID: 9490946
[TBL] [Abstract][Full Text] [Related]
18. Influence of the hepatobiliary contrast agent mangafodipir trisodium (MN-DPDP) on the imaging properties of abdominal organs.
Jung G; Heindel W; Krahe T; Kugel H; Walter C; Fischbach R; Klaus H; Lackner K
Magn Reson Imaging; 1998 Oct; 16(8):925-31. PubMed ID: 9814775
[TBL] [Abstract][Full Text] [Related]
19. MRI for detection of hepatocellular carcinoma: comparison of mangafodipir trisodium and gadopentetate dimeglumine contrast agents.
Youk JH; Lee JM; Kim CS
AJR Am J Roentgenol; 2004 Oct; 183(4):1049-54. PubMed ID: 15385303
[TBL] [Abstract][Full Text] [Related]
20. [Organ specific MRI contrast media in general practice].
Schima W
Wien Med Wochenschr Suppl; 2002; (113):8-11. PubMed ID: 12621828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
